title: Acute antibody-mediated rejection in kidney transplant recipients.
abstract: Antibody-mediated rejection has now been recognized as one of the most important causes of graft loss. Transplantation across HLA barriers and nonadherence can result in acute antibody-mediated rejection, which is associated with particularly worse graft outcomes. New technologies, including genomic studies and assays to detect and define donor-specific antibodies, have provided important insights into the pathophysiology and diagnosis of acute antibody-mediated rejection but have engendered many questions about the clinical application of these tests in the prognosis and prevention of this protean disease process. In this article, we review the pathophysiology of acute antibody-mediated rejection, the evolving diagnostic criteria, and specific challenges related to its prognosis, treatment, and prevention.
authors.affiliation: Division of Renal Disease and Hypertension, Transplant Center, University of Colorado Denver.
authors.forename: Scott
authors.initials: S
authors.lastname: Davis
authors.affiliation: Division of Renal Disease and Hypertension, Transplant Center, University of Colorado Denver. Electronic address: James.Cooper@ucdenver.edu.
authors.forename: James E
authors.initials: JE
authors.lastname: Cooper
mesh_terms: D000208:Acute Disease; D005260:Female; D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control*; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000601:surgery*; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000379:methods; D008297:Male; D011300:Preoperative Care / Q000379:methods; D011322:Primary Prevention / Q000379:methods; D011379:Prognosis; D018570:Risk Assessment; D066027:Transplant Recipients; D014181:Transplantation Immunology / Q000502:physiology
chemical_list: D006680:HLA Antigens